C000078112 Fees and Costs — Health Sciences Portfolio, Class I
Data updated: 2026-08-11
The net expense ratio is 1.15%: a 0.90% management fee, a 0.20% 12b-1 fee plus 0.05% other expenses. There are no sales loads or redemption fees. In fiscal 2025 the fund paid $77K in broker commissions, 0.0206% of average net assets, and portfolio turnover was 54%.
C000078112 Fees and Expenses
Annual operating expenses and sales charges of C000078112. Prospectus, as of April 30, 2026.
| Annual operating expenses | |
|---|---|
| Management fee | 0.90% |
| 12b-1 fee | 0.20% |
| Other expenses | 0.05% |
| Gross expense ratio | 1.15% |
| Fee waiver | — |
| Net expense ratio | 1.15% |
| Sales charges | |
|---|---|
| Max front load | — |
| Max deferred load | — |
| Redemption fee | — |
| Expense limitation in place (N-CEN) | Yes |
| Fees waived or reduced during the year | Yes |
| Waived fees subject to recoupment | No |
C000078112 Costs Over Time
On $10,000 invested in C000078112, assuming 5% a year before costs, total costs come to $730 over 5 years, cutting the return by 1.23% a year. Illustration, not a forecast: it assumes today's net expense ratio throughout (a fee waiver may end).
| $10,000 invested | Sell after 1 year | Sell after 3 years | Sell after 5 years |
|---|---|---|---|
| Value before costs | $10,500 | $11,576 | $12,763 |
| Fund expenses (net expense ratio 1.15%) | $121 | $376 | $651 |
| Trading costs (broker commissions) | $2 | $7 | $12 |
| Lost growth on money paid in costs | $0 | $19 | $67 |
| Total costs | $123 | $402 | $730 |
| Value after costs | $10,377 | $11,174 | $12,033 |
| Impact on return, per year | 1.23% | 1.23% | 1.23% |
C000078112 Trading Costs
Brokerage costs reported on SEC Form N-CEN for the fiscal year ending December 31, 2025.
- Explicit cost rate (commissions ÷ average net assets): 0.0206%
- Total broker commissions: $77K
- Bought from dealers (principal trades, not a cost): $5.8M
- Portfolio turnover (prospectus): 54%
- Securities on loan, average value: $1.4M
- Net income from securities lending: $27K (0.007% of average net assets)
C000078112 Agency Brokers
Commissions paid.
| Broker | Amount | Share |
|---|---|---|
| BofA Securities, Inc. | $13K | 17.85% |
| Morgan Stanley & Co. LLC | $12K | 15.90% |
| Goldman Sachs & Co. LLC | $10K | 13.49% |
| Barclays Capital Inc. | $10K | 13.14% |
| Jefferies LLC | $9K | 11.95% |
| Citigroup Global Markets Inc. | $6K | 7.47% |
| J.P. Morgan Securities LLC | $5K | 6.56% |
| Oppenheimer & Co. Inc. | $4K | 5.90% |
| UBS Securities LLC | $4K | 5.89% |
| BNY Capital Markets, LLC | $1K | 1.86% |
C000078112 Dealer Counterparties
Securities bought directly from dealers (principal trades).
| Broker | Amount | Share |
|---|---|---|
| Goldman Sachs & Co. LLC | $1.6M | 38.49% |
| Leerink Partners LLC | $1.1M | 25.32% |
| J.P. Morgan Securities LLC | $961K | 23.14% |
| Jefferies LLC | $398K | 9.58% |
| BofA Securities, Inc. | $144K | 3.47% |
Health Sciences Portfolio Share Classes
Net expense ratio and maximum front-end load of each share class, cheapest first.
| Ticker | Class | Net expense ratio | Front load |
|---|---|---|---|
| C000098971 | Class P | 0.95% | — |
| C000078112 | Class I | 1.15% | — |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.